Laurion Capital Management’s Standard BioTools LAB Stock Holding History

Laurion Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-300,010	Closed	-$813K	–	665
2024 Q1	$813K	Hold	300,010	–	–	0.01%	395
2023 Q4	$663K	Buy	+300,010	New	+$640K	0.01%	372
2022 Q3	–	Sell	-24,188	Closed	-$39K	–	548
2022 Q2	$39K	Buy	+24,188	New	+$59.8K	﹤0.01%	438
2019 Q1	–	Sell	-94,300	Closed	-$812K	–	1088
2018 Q4	$812K	Buy	+94,300	New	+$735K	0.01%	608

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Laurion Capital Management's LAB Position: Q2 2024 in Review

Laurion Capital Management sold out of Standard BioTools (LAB) in Q2 2024, closing a stake of 300,010 shares — an estimated $813K sold.

Laurion Capital Management first reported a position in LAB in Q4 2018 and held it in 4 quarters. The position peaked at $813K in Q1 2024. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2024.

Laurion Capital Management reported no remaining Standard BioTools position as of Q2 2024 after selling out during the quarter.
Laurion Capital Management sold 300,010 Standard BioTools shares in Q2 2024, an estimated $813K.
Laurion Capital Management first reported a position in Standard BioTools in Q4 2018 and held it in 4 quarters.
Laurion Capital Management's Standard BioTools position peaked at $813K in Q1 2024.
144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.